| Name | Title | Contact Details |
|---|---|---|
George Francis |
Chief Information Officer | Profile |
Jonathan Waldern |
Chief Technology Officer | Profile |
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
To transform research concepts from the lab to clinic-ready products.Integral BioSystems was founded by drug development experts with many years of combined expertise in pharmaceutics and the development of drug products. The company is based in the greater Boston area.
Enthrive is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pierrel Research is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.